Possible scenario
Liability Scrutiny Widens
28% Chance
The program expands beyond care delivery into a broader federal review of vaccine-safety decisions. Investors focus on whether HHS, FDA, and CDC will revisit prior Covid-shot recommendations, pregnancy guidance, or manufacturer disclosures.
Secondary impacts
- Healthcare -1.5%
Tickers
- MRNA-4.3%
- NVAX-2.4%
- PFE-2.3%
- MRK-0.4%
Portfolio impact
S&P 500-0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.